AMP Squared Capital Partners, a private equity firm, led a $29.5m Series A funding round in Theradaptive, a biopharmaceutical company specializing in targeted regenerative therapeutics, with participation from Maryland Venture Fund and OrthoRebirth. "We're delighted that our investors recognize the potential of the Theradaptive platform across indications, from cancer to orthopedics. Support from our partners is essential to continue our work to make existing biologics more precise, persistent, and localized, and thus safer and more effective. Our mission is to offer new treatment possibilities to patients who currently have few options, and this funding will help us achieve this," David Stewart, Theradaptive VP of Operations.